{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:15:31Z","timestamp":1776867331650,"version":"3.51.2"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000180"],"award-info":[{"award-number":["82000180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170205"],"award-info":[{"award-number":["82170205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130003"],"award-info":[{"award-number":["82130003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Key R&D Program","award":["2021C03010"],"award-info":[{"award-number":["2021C03010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are situations where non-first-degree (NFD) related donors have to be considered as alternatives to first-degree (FD) related donors for haploidentical hematopoietic cell transplantation (HAPLO). However, the efficacy of these NFD related transplants remains uncertain. All consecutive adult patients (\u2265\u200918\u00a0years) with acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL) in CR who underwent a first HAPLO between 2010 and 2021 in the European Society for Blood and Marrow Transplantation (EBMT) registry were analyzed. Exact matching and propensity score matching was used. The NFD-to-FD ratio was 1:3. 2703 patients (AML: n\u2009=\u20092047; ALL: n\u2009=\u2009656) in CR received a first HAPLO from either NFD (n\u2009=\u2009154) or FD (n\u2009=\u20092549) related donors in 177 EBMT centers. 123 NFD and 324 FD HAPLO were included for analysis after matching. Median patient age was 35.6 and 37.2 for the NFD and FD cohorts, respectively. Both cohorts reached good engraftment rates (NFD: 95.7% vs. FD, 95.6%; p\u2009=\u20090.78). The 2-year relapse incidence (NFD, 21.1% vs. FD, 22.6%; p\u2009=\u20090.84) and non-relapse mortality (NRM) (NFD, 13.2% vs. FD, 17.7%; p\u2009=\u20090.33) were not significantly different. The 2-year overall survival (OS) (NFD, 71.8% vs. FD, 68.3%; p\u2009=\u20090.56), leukemia-free survival (LFS) (NFD, 65.7% vs. FD, 59.7%; p\u2009=\u20090.6) and graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) (NFD, 50.9% vs. FD, 47.8%; p\u2009=\u20090.69) also showed no significant differences. The two cohorts showed no difference in terms of cumulative day 180 grade II-IV, grade III-IV acute GVHD, 2-year cumulative incidences of chronic and extensive chronic GVHD. For HAPLO in patients with acute leukemia, NFD related donors could be equivalent substitutions when FD related donors are not available.\n<\/jats:p>","DOI":"10.1186\/s13045-023-01421-9","type":"journal-article","created":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T12:02:23Z","timestamp":1679140943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1186","volume":"16","author":[{"given":"Yishan","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Gulbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Polge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Houhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert-Claude","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","volume":"35","author":"A Bashey","year":"2017","unstructured":"Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell\u2013replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017;35:3002\u20139.","journal-title":"J Clin Oncol"},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956\u201362.","journal-title":"Blood"},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical versus matched-sibling transplant in adults with philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22:3467\u201376.","journal-title":"Clin Cancer Res"},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, de la C\u00e1mara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651\u201364. https:\/\/doi.org\/10.1038\/s41409-021-01227-8.","journal-title":"Bone Marrow Transpl"},{"key":"1421_CR6","first-page":"4","volume":"2022","author":"M Wieczorek","year":"2022","unstructured":"Wieczorek M, Labopin M, Castagna L, Brissot E, Soci\u00e9 G, Raiola AM, et al. Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5\/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: a study on behalf of the ALWP of the EBMT. Am J Hematol. 2022;2022:4\u20137.","journal-title":"Am J Hematol"},{"key":"1421_CR7","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","volume":"24","author":"H Elmariah","year":"2018","unstructured":"Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biol Blood Marrow Transpl. 2018;24:1099\u2013102. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.005.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/bmt.2013.223","volume":"49","author":"YY Zhang","year":"2014","unstructured":"Zhang YY, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. Bone Marrow Transplant. 2014;49:496\u2013501.","journal-title":"Bone Marrow Transplant"},{"key":"1421_CR9","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.scib.2018.08.008","volume":"63","author":"XD Mo","year":"2018","unstructured":"Mo XD, Zhang YY, Zhang XH, Xu LP, Wang Y, Yan CH, et al. The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Sci Bull. 2018;63:1376\u201382. https:\/\/doi.org\/10.1016\/j.scib.2018.08.008.","journal-title":"Sci Bull"},{"key":"1421_CR10","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1038\/s41409-021-01352-4","volume":"56","author":"Y Ye","year":"2021","unstructured":"Ye Y, Wang M, Malard F, Shi J, Lu Y, Ouyang G, et al. Comparison of non-first-degree related donors and first-degree related donors in haploidentical HSCT: a multi-centre retrospective analysis. Bone Marrow Transpl. 2021;56:2567\u201374. https:\/\/doi.org\/10.1038\/s41409-021-01352-4.","journal-title":"Bone Marrow Transpl"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01421-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T12:02:48Z","timestamp":1679140968000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01421-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01421-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,18]]},"assertion":[{"value":"13 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific board of the ALWP of EBMT approved this study. All patients gave written informed consent for the use of their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for individual patient data. This is a pooled analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}